Taysha Gene Therapies, Inc. (TSHA) — Financial statements
Income statement, balance sheet, and cash flow for Taysha Gene Therapies, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 10↑17.3% | 8↓46.1% | 15↑517.5% | 3 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 2 | 0.00 | |
| Gross Profit | 10↑17.3% | 8↓46.1% | 15↑102913.5% | 0.01 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 86↑30.9% | 66↑16.2% | 57↓37.7% | 91↓30.9% | 132 | |
| General & Administrative Expenses | 34↑17.0% | 29↓3.6% | 30 | 0.00↓100.0% | 41 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 34↑17.0% | 29↓3.6% | 30↓13.8% | 35↓15.6% | 41 | |
| Other Expenses | 0.00↓100.0% | 5↑354.3% | 1 | 0.00 | 0.00 | |
| Operating Expenses | 120↑20.5% | 100↑13.5% | 88↓30.3% | 126↓27.3% | 173 | |
| Total Costs & Expenses | 120↑20.5% | 100↑13.5% | 88↓31.6% | 129↓25.8% | 173 | |
| Operating Results | ||||||
| Operating Income | -110↓20.8% | -91↓26.3% | -72↑42.5% | -126↑27.3% | -173 | |
| Depreciation & Amortization | 1↓8.0% | 1↓9.2% | 1↓44.9% | 2↑405.5% | 0.49 | |
| EBITDA | -108↓22.6% | -88↑16.4% | -105↑34.1% | -160↑7.5% | -173 | |
| EBIT | -109↓22.1% | -89↑16.3% | -107↑34.3% | -162↑6.3% | -173 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↑34.0% | 7↑579.5% | -1↑59.8% | -4↓182.6% | -1 | |
| Interest Income | 9↑32.9% | 7↑94.3% | 4↑1334.5% | 0.25↑44.8% | 0.17 | |
| Interest Expense | 0.06↓38.2% | 0.10↓98.0% | 5↑31.6% | 4↑166.0% | 1 | |
| Non-Operating Income | -2↑30.8% | -2↓106.6% | 34↓5.7% | 36↑21140.1% | -0.17 | |
| Other Income / Expenses | 2↓30.4% | 2↑105.5% | -39↑2.2% | -40↓3083.7% | -1 | |
| Income Before Tax | -109↓22.1% | -89↑20.0% | -112↑32.8% | -166↑4.9% | -175 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -109↓22.1% | -89↑20.0% | -112↑32.8% | -166↑4.9% | -175 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -109↓22.1% | -89↑20.0% | -112↑32.8% | -166↑4.9% | -175 | |
| Bottom-Line Net Income | -109↓22.1% | -89↑20.0% | -112↑32.8% | -166↑4.9% | -175 | |
| EPS (Basic) | -0.34↑5.6% | -0.36↑62.5% | -0.96↑74.6% | -3.78↑18.5% | -4.64 | |
| EPS (Diluted) | -0.34↑5.6% | -0.36↑62.5% | -0.96↑74.6% | -3.78↑18.5% | -4.64 | |
| Weighted Average Shares | 320↑27.8% | 250↑115.4% | 116↑164.2% | 44↑16.7% | 38 | |
| Weighted Average Diluted Shares | 320↑27.8% | 250↑115.4% | 116↑164.2% | 44↑16.7% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.